The study engineered a site-specific covalent albumin-CpG conjugate to engage human FcRn (hFcRn) for enhanced lymph node targeting and immune activation. Using genO-HSA/hFcRn humanized mice, the conjugate demonstrated prolonged systemic exposure, lymph node accumulation, and potent TLR9-driven immune stimulation, outperforming unmodified CpG or non-covalent mixtures.
Covalent HSA‑CpG improves CpG exposure, lymphatic uptake, and TLR9 activation; immune potentiation confirmed in hFcRn/HSA context; conjugate shows dose-sparing potential for immunostimulatory therapies
genO‑hSA/hFcRn humanized Knockin mouse — genOway-developed, expressing both human serum albumin (HSA) and human FcRn, replacing the mouse counterparts
Innate immunity, FcRn‑targeted delivery, CpG oligonucleotide therapy, TLR9 agonists, lymph node targeting, humanized immune models
Humanized Knockin model, HSA Knockin, hFcRn Knockin, Albumin–FcRn interaction studies
From model design to experimental results
Featured in 600+ scientific articles
Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions
Generated with biopharma partners and in-house
and guaranteed freedom to operate
Models with certified health status from professional breeders in US and Europe
